News from other websites on Natco Pharma
Big Pharma on the backfoot in India
Nov 29, 2012 at 23:41 | Source: Business Today
E. Kumar SharmaThe Intellectual Property Appellate Board's (IPAB) decision to deny patent protection to AstraZeneca for its lung cancer drug Gefitinib is the latest setback for a Big Pharma company in India. Big Pharma refers to global pharmaceutica...
AstraZeneca drug appeal dismissed
Nov 29, 2012 at 19:16 | Source: Business Standard
In a setback to multinational drug major AstraZeneca, the Intellectual Property Appellate Board (IPAB) has dismissed its appeal against an earlier ruling that refused it a patent on lung cancer drug Gefitinib. The London-headquartered pharmaceutical ...
Nov 29, 2012 at 18:36 | Source: Business Standard
Natco Pharma has surged 7% to Rs 448 on reports that the Intellectual Property Appellate Board (IPAB) dismissed AstraZeneca appeal on lung cancer drug Gefitinib. AstraZeneca's attempt to seek patent for Gefitinib was first turned down by the Indian ...
IPAB turns down AstraZeneca plea for cancer drug patent again
Nov 29, 2012 at 14:41 | Source: Business Today
Intellectual Property Appellate Board (IPAB) has again turned down drug firm AstraZeneca's plea for a patent on the lung cancer drug Gefitinib.IPAB on November 26 upheld its earlier decision to refuse AstraZeneca a patent claim in 2007, citing lack ...
Patents appeal board rejects AstraZeneca's patent plea on cancer drug
Nov 29, 2012 at 07:20 | Source: Economic Times
HYDERABAD: AstraZeneca has been denied patent protection for its anti-cancer drug Gefitinib, becoming the latest multinational pharmaceutical company to run afoul of India's patent law. On Monday, the Intellectual Property Appellate Board ruled the ...
IPAB dismisses Astra Zeneca’s cancer drug patent appeal
Nov 29, 2012 at 01:31 | Source: The Hindu BusinessLine
The Intellectual Property Appellate Board has dismissed an appeal by British drug-maker Astra Zeneca on its cancer drug Gefitinib. The multinational drug-maker had approached the Intellectual Property Appellate Board (IPAB), challenging the rulings ...
Nov 28, 2012 at 20:11 | Source: Business Standard
In a set back to multi-national drug major AstraZeneca, the Intellectual Property Appellate Board (I PAB) has dismissed the company's appeal against refusal of patent to lung cancer drug Gefitinib. The London-headquartered pharmaceutical and biologic...
Cipla slashes cancer drug prices by 64%
Nov 08, 2012 at 21:10 | Source: DNA India
Drug major Cipla today slashed prices of its three generic cancer drugs -- Erlocip, Docetax and Capegard -- by up to 64%. The drugs are used for treating lung and pancreatic cancer, breast cancer, head neck cancer, gastric cancer, bladder, colorectal...
Results expected...RCOM, ONGC in focus
Nov 08, 2012 at 01:17 | Source: India Infoline
The results which are expected: Aditya Birla Nuv, SAIL, Allcargo Logistics, Alstom T D, Alembic, Asian Hotels (West), Asahi India, Ashoka Buildcon, Ashok Leyland, Career Point, DynamaticTech, CMS Infotech, Cummins India, Dalmia, Bharat Ent, CMS Info...
Roche patent revocation may have a bearing on other cases
Nov 04, 2012 at 17:56 | Source: Business Today
E. Kumar SharmaThe concluding line of the order was terse: "The grant of Patent No.198952 is set aside. M.P.No.85 of 2012 is dismissed and M.P.No.111 of 2012 is ordered. No costs."With those words, delivered on Friday, November 2, India's Intellectu...
Industry watchdogs rise to the occasion
Oct 09, 2012 at 21:41 | Source: Business Today
In March last year, three months after E.K. Bharat Bhushan took over as head of the Directorate General of Civil Aviation (DGCA), a pilot of IndiGo Airlines made a faulty landing at Goa airport. The Airbus she was steering touched down on its nose w...
Pfizer to challenge patent revocation of cancer drug
Oct 05, 2012 at 17:31 | Source: The Hindu BusinessLine
New Delhi, Oct 5: Drug firm Pfizer India today said it will appeal against a ruling by Indian Patents Office, which has revoked patent for its cancer drug Sutent. The Indian Patents Office last month issued an order revoking Pfizer’s patent of...
Oct 04, 2012 at 21:17 | Source: Business Standard
Giving another blow to MNC drug majors, the Indian patent office has revoked US-based Pfizer's patent for cancer drug Sutent in India. The Delhi patent office has rejected Pfizer's claim for the patent over Sutent, saying Pfizer's patent does not inv...
No stay on compulsory licence to Natco: IPAB
Sep 19, 2012 at 05:06 | Source: Business Standard
The Intellectual Property Appellate Board has dismissed a stay petition filed by Bayer Corporation, the US arm of German drug maker Bayer AG, against the compulsory licence issued by the Indian Patent Authority to Natco Pharma to manufacture generic ...
Patent rights, a fillip for Natco Pharma
Sep 17, 2012 at 01:31 | Source: The Hindu BusinessLine
The stock of Natco Pharma will see some buying interest after the Intellectual Property Appellate board rejected Bayer Corporation’s petition seeking a stay on the compulsory licence granted to the former. In March this year Natco Pharma got t...
Bayer’s appeal for stay on compulsory licence to Natco Pharma rejected
Sep 15, 2012 at 23:11 | Source: The Hindu BusinessLine
Chennai, Sept 15: The Intellectual Property Appellate Board has rejected pharma major Bayer Corporation’s petition seeking a stay on the compulsory licence granted to Hyderabad-based Natco Pharma Ltd. The Controller of Patents had on March 9 g...
DoP to seek public opinion on pricing for patented drugs
Sep 14, 2012 at 20:08 | Source: The Hindu BusinessLine
The Department of Pharmaceuticals will seek views from stakeholders on how patented drugs must be priced in the country and will put up draft guidelines in public domain by next week, a senior official said today. “A draft note on pricing mech...
‘Patent drug prices should be set after negotiations with pharma cos’
Sep 09, 2012 at 20:16 | Source: FirstPost
A panel set up to look into the pricing mechanism for patented drugs has said that prices have to be decided after deliberations with manufacturers if the government is to adopt price negotiation model, Parliament was informed. A committee was set u...
`Fixing of patented drug prices only after negotiating with pharma cos’
Sep 07, 2012 at 21:37 | Source: The Hindu BusinessLine
A panel set up to look into the pricing mechanism for patented drugs has said that prices have to be decided after deliberations with manufacturers if the government is to adopt price negotiation model, Parliament was informed today.A committee was ...
Sep 06, 2012 at 08:51 | Source: Business Standard
The outcome of the case will have huge ramifications. Much of the world from patients to pharmaceutical companies to health activists and even governments is watching an intense battle currently being fought by Swiss pharma giant Novartis in India s ...
From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'
